Overview

PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma

Status:
Active, not recruiting

Trial end date:
2023-04-28

Target enrollment:

Participant gender:

Summary

To assess the safety and tolerability at increasing dose levels of PF-06863135 in patients with relapse/ refractory multiple myeloma in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.

Phase:

Phase 1

Details

Lead Sponsor:

Pfizer

Treatments:

Antibodies
Antibodies, Bispecific
BB 1101
Dexamethasone
Dexamethasone acetate
Immunoglobulins
Lenalidomide
Pomalidomide
Thalidomide